Literature DB >> 31854002

Evaluation of an autoregulatory ECMO system for total respiratory support in an acute ovine model.

Robert G Conway1, Zachary B Berk1, Jiafeng Zhang1, Tieluo Li1, Douglas Tran1, Zhongjun J Wu1,2, Bartley P Griffith1.   

Abstract

Extracorporeal membrane oxygenation (ECMO) has become a mainstay of therapy for patients suffering from severe respiratory failure. Ambulatory ECMO systems aim to provide long-term out-of-hospital respiratory support. As a patient's activity level changes, the required level of ECMO support varies with oxygen consumption and metabolic fluctuations. To compensate for such changes, an autoregulatory ECMO system (AR-ECMO) has been developed and its performance was evaluated as a proof of concept in an acute ovine model. The AR-ECMO system consists of a regular ECMO circuit and an electromechanical control system. A custom fuzzy logic control algorithm was implemented to adjust the blood flow and sweep gas flow of the ECMO circuit to meet the varying respiratory demand by utilizing two noninvasive sensors for venous oxyhemoglobin saturation and the oxygenator exhaust gas CO2 concentration. Disturbance responses of the AR-ECMO to induced acute respiratory distress were assessed for six hours in four juvenile sheep cannulated with a veno-pulmonary artery ECMO configuration, including acute ventilator shutoff, ventilator step change (off-on-off), and forced desaturation. All sheep survived for the study duration. The AR-ECMO system was able to respond and maintain stable hemodynamics and physiological blood gas contents (SpO2  = 96.3 % ± 4.29, pH 7.44 ± 0.09, pCO2  = 38.9 ± 9.9 mm Hg, and pO2 =237.9 ± 123.6 mm Hg) during simulated respiratory distress. Acceptable correlation between oxygenator exhaust gas CO2 and oxygenator outlet pCO2 were observed (R2  = 0.84). In summary, the AR-ECMO system successfully maintained physiologic control of peripheral oxygenation and carbon dioxide over the study period, utilizing only measurements taken directly from the ECMO circuit. The range of system response necessitates an adaptable system in the setting of variable metabolic demands. The ability of this system to respond to significant disturbances in ventilator support is encouraging. Future work to evaluate our AR-ECMO system in long-term, awake animal studies is necessary for further refinement.
© 2020 International Center for Artificial Organs and Transplantation and Wiley Periodicals, Inc.

Entities:  

Keywords:  artificial lung; autoregulatory control; extracorporeal membrane oxygenation; respiratory distress

Mesh:

Year:  2020        PMID: 31854002      PMCID: PMC7165054          DOI: 10.1111/aor.13618

Source DB:  PubMed          Journal:  Artif Organs        ISSN: 0160-564X            Impact factor:   3.094


  13 in total

1.  Ambulatory extracorporeal membrane oxygenation: a new approach for bridge-to-lung transplantation.

Authors:  Jose P Garcia; Aldo Iacono; Zachary N Kon; Bartley P Griffith
Journal:  J Thorac Cardiovasc Surg       Date:  2010-03-09       Impact factor: 5.209

2.  Long-term support with an ambulatory percutaneous paracorporeal artificial lung.

Authors:  Xiaoqin Zhou; Dongfang Wang; Ryan Sumpter; Gary Pattison; Cherry Ballard-Croft; Joseph B Zwischenberger
Journal:  J Heart Lung Transplant       Date:  2012-03-22       Impact factor: 10.247

3.  Automation of a portable extracorporeal circulatory support system with adaptive fuzzy controllers.

Authors:  A Mendoza García; M Krane; B Baumgartner; N Sprunk; U Schreiber; S Eichhorn; R Lange; A Knoll
Journal:  Med Eng Phys       Date:  2014-06-02       Impact factor: 2.242

4.  Thirty-day in-vivo performance of a wearable artificial pump-lung for ambulatory respiratory support.

Authors:  Zhongjun J Wu; Tao Zhang; Giacomo Bianchi; Xufeng Wei; Ho-Sung Son; Kang Zhou; Pablo G Sanchez; Jose Garcia; Bartley P Griffith
Journal:  Ann Thorac Surg       Date:  2011-11-25       Impact factor: 4.330

5.  Ambulatory veno-venous extracorporeal membrane oxygenation: innovation and pitfalls.

Authors:  Jose P Garcia; Zachary N Kon; Charles Evans; Zhongjun Wu; Aldo T Iacono; Brian McCormick; Bartley P Griffith
Journal:  J Thorac Cardiovasc Surg       Date:  2011-10       Impact factor: 5.209

6.  In vitro and in vivo evaluation of a novel integrated wearable artificial lung.

Authors:  Shalv P Madhani; Brian J Frankowski; Greg W Burgreen; Jim F Antaki; Robert Kormos; Jonathan D'Cunha; William J Federspiel
Journal:  J Heart Lung Transplant       Date:  2017-03-04       Impact factor: 10.247

7.  Extracorporeal Membrane Oxygenation for End-Stage Interstitial Lung Disease With Secondary Pulmonary Hypertension at Rest and Exercise: Insights From Simulation Modeling.

Authors:  Scott Chicotka; Daniel Burkhoff; Marc L Dickstein; Matthew Bacchetta
Journal:  ASAIO J       Date:  2018 Mar/Apr       Impact factor: 2.872

8.  Membrane oxygenator exhaust capnography for continuously estimating arterial carbon dioxide tension during cardiopulmonary bypass.

Authors:  Kieron C Potger; Darryl McMillan; Joanne Southwell; Hayden Dando; Killian O'Shaughnessy
Journal:  J Extra Corpor Technol       Date:  2003-09

9.  In Vivo 5 Day Animal Studies of a Compact, Wearable Pumping Artificial Lung.

Authors:  Shalv P Madhani; Brian J Frankowski; Sang-Ho Ye; Greg W Burgreen; William R Wagner; Robert Kormos; Jonathan D'Cunha; William J Federspiel
Journal:  ASAIO J       Date:  2019-01       Impact factor: 2.872

10.  Early mobilization of patients receiving extracorporeal membrane oxygenation: a retrospective cohort study.

Authors:  Darryl Abrams; Jeffrey Javidfar; Erica Farrand; Linda B Mongero; Cara L Agerstrand; Patrick Ryan; David Zemmel; Keri Galuskin; Theresa M Morrone; Paul Boerem; Matthew Bacchetta; Daniel Brodie
Journal:  Crit Care       Date:  2014-02-27       Impact factor: 9.097

View more
  1 in total

1.  Toward a Servoregulation Controller to Automate CO2 Removal in Wearable Artificial Lungs.

Authors:  Joseph A Potkay; Alex J Thompson; John Toomasian; William Lynch; Robert H Bartlett; Alvaro Rojas-Peña
Journal:  ASAIO J       Date:  2021-08-06       Impact factor: 3.826

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.